Kezar Life Sciences
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $1,042 | $0 |
Gross Profit | -251 | 521 | -260 | |
EBITDA | -14,599 | -15,958 | -19,570 | -19,650 |
EBIT | -16,209 | -19,829 | -19,910 | |
Net Income | -13,704 | -16,556 | -20,218 | -20,313 |
Net Change In Cash | 0 | 0 | 1,042 | 0 |
Free Cash Flow | -12,795 | -17,198 | -16,836 | -17,512 |
Cash | 34,367 | 37,002 | 41,749 | 34,858 |
Basic Shares | 7,311 | 7,305 | 7,300 | 72,962 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $0 | $7,000 | $0 | $0 |
Gross Profit | -1,040 | 5,934 | -1,022 | -1,510 |
EBITDA | -81,103 | -99,254 | -70,139 | -52,961 |
EBIT | -82,143 | -100,320 | -71,162 | -54,471 |
Net Income | -83,736 | -101,870 | -65,316 | -54,630 |
Net Change In Cash | 0 | 7,000 | 0 | 0 |
Cost of Revenue | -22,377 | 41,704 | ||
Free Cash Flow | -74,241 | -83,455 | -60,424 | -42,753 |
Cash | 41,749 | 35,493 | 40,456 | 62,882 |
Basic Shares | 72,902 | 72,553 | 67,368 | 52,759 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$1.87 |
2025-03-31 | -$2 |
2024-12-31 | -$3 |
2024-09-30 | -$2.78 |
